Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromosome 19 open reading frame 33 (C19orf33)
- Target
- C19orf33
- Molecular classification
- Other (protein coding gene, not classified as receptor, enzyme, transporter, transcription factor, channel, or histone modifier)
01
Overview
Chromosome 19 open reading frame 33 (C19orf33) is a protein-coding gene whose protein product is known as Immortalization-upregulated protein. The protein, which has two transcript variants (IMUP-1 and IMUP-2), is primarily localized to the nucleus but may also be found in the cytosol and at the plasma membrane. Its expression is upregulated in SV40-immortalized fibroblasts and various carcinoma cell types. The protein is suggested to play roles in placental development and diseases such as pre-eclampsia, as well as in endometrial and pancreatic cancers. Mechanistically, it is associated with DNA binding and possibly with cell proliferation, apoptosis, and cancer-related signaling pathways, but does not belong to conventional drug-target classes like receptors or enzymes.
- Other names
- Immortalization-upregulated proteinIMUPIMUP-1IMUP-2H2RSPHepatocyte growth factor activator inhibitor type 2-related small proteinC19orf33
02
Biological functions
DNA binding (double-stranded and single-stranded)Probable roles in placental developmentProbable involvement in cell immortalization and upregulation in immortalized cell linesMay function in cell proliferation and apoptosis, especially in specific disease states
03
Disease associations
Pre-eclampsia (especially via IMUP-2 upregulation and apoptosis of trophoblasts)Endometrial carcinoma and other cancers (upregulated expression in cancer cell lines; associated with poor prognosis in pancreatic adenocarcinoma)
04
Biomarkers
It may serve as a prognostic biomarker in certain cancers, such as pancreatic adenocarcinoma, where high expression correlates with poor recurrence-free and overall survival
Beyond the preview
Go deeper on Chromosome 19 open reading frame 33 (C19orf33).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chromosome 19 open reading frame 33 (C19orf33).